On Wednesday, the World Health Organization (WHO) approved the first ever vaccine for the prevention of malaria. Officials with the organization called it a “glimmer of hope” for Africa.
The WHO recommendation is for RTS,S, or Mosquirix, a vaccine developed by British drugmaker GlaxoSmithKline.
Since 2019, 2.3 million doses of Mosquirix have been administered to infants in Ghana, Kenya and Malawi as part of a large-scale pilot program coordinated by the health agency.
Malaria killed approximately 386,000 Africans in 2019, according to a WHO estimate. The majority of those killed by the disease were children.
Malaria is caused by parasites transmitted through the bite of an infected mosquito.
For more info, please go to https://globalnews.ca/news/8247780/malaria-vaccine-who/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#Mosquirix #Health #malaria #GlobalNews
The WHO recommendation is for RTS,S, or Mosquirix, a vaccine developed by British drugmaker GlaxoSmithKline.
Since 2019, 2.3 million doses of Mosquirix have been administered to infants in Ghana, Kenya and Malawi as part of a large-scale pilot program coordinated by the health agency.
Malaria killed approximately 386,000 Africans in 2019, according to a WHO estimate. The majority of those killed by the disease were children.
Malaria is caused by parasites transmitted through the bite of an infected mosquito.
For more info, please go to https://globalnews.ca/news/8247780/malaria-vaccine-who/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#Mosquirix #Health #malaria #GlobalNews
- Category
- U.S. & Canada
- Tags
- global news, malaria, malaria vaccine
Sign in or sign up to post comments.
Be the first to comment